Philmans Pharm, Cenedella.de, The German Patient Roundtable

Est. 1977

Canopy Growth’s Bedrocan Canada unit is taking Bedrocan International to arbitration for contractual dispute.

http://www.newswire.ca/news-releases/bedrocan-canada-commences-arbitration-proceedings-under-licensing-and-distribution-agreement-with-bedrocan-international-634545013.html
Bedrocan Canada commences arbitration proceedings under licensing and distribution agreement with Bedrocan International

Impact of Dispute on Canopy Growth and its Customers to be Negligible

SMITHS FALLS, ON, July 14, 2017 /CNW/ – Bedrocan Canada Inc. (“Bedrocan Canada”), a wholly-owned subsidiary of Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (OTC: TWMJF) has commenced arbitration proceedings against Bedrocan International BV (“Bedrocan International” or the “Licensor”) seeking performance of Bedrocan International’s contractual obligations under the licensing and distribution agreement between the parties (the “LDA”).

Bedrocan Canada asserts the Licensor has withdrawn and/or withheld services, designs, and support contrary to the Licensor’s contractual obligations. Because of this, and due to the fact that Bedrocan International procedures cannot be altered independently of the Licensor, Bedrocan Canada is now seeking redress through the process set out in the LDA.

Canopy Growth, then operating as Tweed Marijuana Inc., completed its acquisition of Bedrocan Canada in August 2015. The acquisition was made in order to diversify the growing platform and brand identities held by the Company. Since this time, Canopy Growth has added a substantial number of brands and growing capacity to its platform. Through this process of expansion, Bedrocan Canada operations have diminished as a percentage of total capacity and brand equity within the Canopy Growth family of companies.

Canopy Growth has established itself as a global leader in cannabis production, research, and physician education. We will continue our aggressive expansion efforts based on the operational knowhow developed at the Tweed, Tweed Farms, and Mettrum facilities. Seeking redress through an arbitration process is necessary to ensure that the Bedrocan Canada asset is maximized for shareholders and operating at maximum efficiency for the good of patients.

Bruce Linton, Chairman and CEO

In spite of the Licensor’s inaction, Canopy Growth has consistently met its contractual obligations as a licensee. The licensed facility operating as Bedrocan Canada remains and will remain an operating asset of Canopy Growth.

The Company is hopeful that with the assistance of arbitration Bedrocan International will comply with its contractual obligations to support its intellectual property with the hope of achieving a greater level of efficiency, reliability and standardization that have become the benchmark of Canopy Growth operations.

Author: Cenedella.de

Over the last 4 decades I have been involved in the fight for patient rights in America, and now here in Germany. During my career I have served as a Board of Director for the World Trade Center San Diego and as a Lead Consultant for Deutsche Telekom's Executive Board, Co-Founded the San Diego Software Council and the Dayton Human Trafficking Accords and was Director of LawInfo's Lead Council Program. Previously I was a C-Level Business Development Executive in the technology sector, but also involved with the cannabis industry since 1977. More recently I have been fulltime in the legal medical marijuana industry here in Europe, helping international companies navigate the biggest potential market in the world. This website is light on details due to confidentiality issues with clients but be rest assured I am knowledgeable, professional and with street cred in the industry that can immediately assist your growth in some way. Consulting Services: Sales and Business Development Assist with Strategic Direction Professionally represent your firm Special Projects management Licensing and compliance Sales and Distribution networks Qualify potential partners I am your resource on the ground in Europe, contact me directly to schedule an initial discussion on the German Cannabis-as-Medicine market. Thank you, Philip J. Cenedella IV Call +1.888.206.3264 USA +49.0.151.720.17652 GERMANY Skype: philip.j.cenedella eMail: phil@cenedella.de LinkedIN: https://www.linkedin.com/in/cenedellade/

Comments are closed.